Cargando…

886. The Impact of the COVID-19 Pandemic on Clinical Follow-Up, Monitoring and Regimen Discontinuation for People Living with HIV in the US

BACKGROUND: The COVID-19 pandemic has disrupted health care services for people living with HIV (PLWH). This study aimed to compare rates of clinical visits, viral load monitoring and antiretroviral therapy (ART) regimen discontinuation among virally suppressed PLWH in the US before and during the C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Henegar, Cassidy, van Wyk, Jean A, Sarkar, Supriya, Vannappagari, Vani, Zolopa, Andrew, Wohlfeiler, Michael B, Fusco, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690744/ http://dx.doi.org/10.1093/ofid/ofab466.1081

Ejemplares similares

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes
por: Hsu, Ricky K., et al.
Publicado: (2023)

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
por: Mounzer, Karam, et al.
Publicado: (2019)

341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
por: Hsu, Ricky, et al.
Publicado: (2019)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study
por: Mounzer, Karam, et al.
Publicado: (2019)

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
por: Sension, Michael, et al.
Publicado: (2023)

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort
por: Hsu, Ricky K, et al.
Publicado: (2023)

Antiretroviral therapy and liver disorders in the OPERA(®) cohort
por: Wohlfeiler, Michael, et al.
Publicado: (2020)

1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
por: Yan, Lei, et al.
Publicado: (2022)

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
por: Lackey, Philip, et al.
Publicado: (2018)

Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization
por: Brunet, Laurence, et al.
Publicado: (2021)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
por: Mallon, Patrick, et al.
Publicado: (2019)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents
por: Mills, Anthony M, et al.
Publicado: (2021)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score
por: Hsu, R, et al.
Publicado: (2020)

Synthesis and reactivity of precolibactin 886
por: Healy, Alan R., et al.
Publicado: (2019)

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens
por: Mounzer, Karam, et al.
Publicado: (2022)

HIV retention in care: results and lessons learned from the Positive Pathways Implementation Trial
por: Wohlfeiler, Michael B., et al.
Publicado: (2022)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Free discontinuity problems
por: Fusco, Nicola, et al.
Publicado: (2016)

2085. PrEP Interest and Preferences Among US Black and Hispanic Men – A National Survey
por: Poteat, Tonia, et al.
Publicado: (2022)

Human noncoding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR
por: Calderon, Brenda M., et al.
Publicado: (2017)

Methylation status of nc886 epiallele reflects periconceptional conditions and is associated with glucose metabolism through nc886 RNAs
por: Marttila, Saara, et al.
Publicado: (2021)

886. Pregnancy Outcomes Following Raltegravir Exposure
por: Shamsuddin, Hala, et al.
Publicado: (2019)

1592. Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study
por: Elion, Rick A, et al.
Publicado: (2023)

1549. Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey
por: Poteat, Tonia, et al.
Publicado: (2023)

Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims database
por: Bratton, Emily, et al.
Publicado: (2017)

2089. Relative patient preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among US men who have sex with men, 2021-2022
por: Sanchez, Travis, et al.
Publicado: (2022)

886. Impact of Race on the Early Diagnosis and Treatment of Lyme Disease
por: Starke, Samuel J, et al.
Publicado: (2023)

Methylation pattern of polymorphically imprinted nc886 is not conserved across mammalia
por: Kostiniuk, Daria, et al.
Publicado: (2022)

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir
por: Vannappagari, Vani, et al.
Publicado: (2019)

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_83h23vvavi97viraiujtu7equa